Skip to main content
Clinical Trials/ISRCTN88858357
ISRCTN88858357
Completed
未知

Real-world study of the management and outcomes of patients with frontline transplant-eligible multiple myeloma in four European countries (France, Germany, Spain and Italy)

Kantar Health (France)0 sites804 target enrollmentNovember 22, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
Frontline transplant-eligible multiple myeloma
Sponsor
Kantar Health (France)
Enrollment
804
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 22, 2021
End Date
August 31, 2021
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Kantar Health (France)

Eligibility Criteria

Inclusion Criteria

  • Study population 1 (ongoing FLTE MM population):
  • 1\. Being on an ongoing frontline therapy line
  • 2\. Being considered either fit for transplant at initial diagnosis, or planned on transplant while on frontline therapy, or having already been transplanted while on frontline therapy
  • Study population 2 (previous FLTE MM population):
  • 1\. Being on an ongoing relapse or refractory multiple myeloma therapy line
  • 2\. Having received a previous frontline therapy line
  • 3\. Being considered either fit for transplant at initial diagnosis, or having already been transplanted while on frontline therapy

Exclusion Criteria

  • Study population 1 (ongoing FLTE MM population):
  • 1\. Receiving the ongoing frontline therapy as part of a randomized controlled trial or early access program
  • Study population 2 (previous FLTE MM population):
  • 1\. Having initiated the frontline induction prior to 2017

Outcomes

Primary Outcomes

Not specified

Similar Trials